Titan Pharmaceuticals Faces Delisting Notice
| Field | Detail |
|---|---|
| Company | Titan Pharmaceuticals Inc |
| Form Type | 8-K |
| Filed Date | Jun 2, 2025 |
| Risk Level | high |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, compliance, regulatory
TL;DR
Titan Pharma got a delisting warning, might get kicked off the exchange.
AI Summary
Titan Pharmaceuticals, Inc. filed an 8-K on June 2, 2025, reporting a notice of delisting or failure to satisfy continued listing rules as of May 30, 2025. The filing also includes financial statements and exhibits.
Why It Matters
This filing indicates potential issues with Titan Pharmaceuticals' compliance with stock exchange listing requirements, which could lead to the company's shares being delisted.
Risk Assessment
Risk Level: high — A notice of delisting directly threatens the liquidity and trading of the company's stock.
Key Players & Entities
- Titan Pharmaceuticals, Inc. (company) — Registrant
- May 30, 2025 (date) — Date of earliest event reported
- June 2, 2025 (date) — Filing date
- 001-13341 (other) — Commission File Number
FAQ
What specific listing rule did Titan Pharmaceuticals fail to satisfy?
The filing does not specify the exact listing rule that was not satisfied, only that a notice of delisting or failure to satisfy a continued listing rule or standard was issued.
What is the date of the notice of delisting?
The earliest event reported, which includes the notice of delisting, is dated May 30, 2025.
What is the company's principal executive office address?
The address of the principal executive offices is 10 East 53rd St., Suite 3001, New York, NY 10022.
What is the company's telephone number?
The registrant's telephone number is (786) 769-7512.
What is the company's state of incorporation?
Titan Pharmaceuticals, Inc. is incorporated in Delaware.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 2, 2025 regarding TITAN PHARMACEUTICALS INC.